Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|October 2, 2001
- Pharmaceutical Technology-10-02-2001
- Volume 25
- Issue 10
Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers
Author(s)Anton Gueth
The author proposes a strategy for achieving a successful partnership with Big Pharma on the basis of forming a relationship with the company, deliberately managing the alliance, and clearly defining roles and responsibilities.
Advertisement
Articles in this issue
almost 25 years ago
Outsourcing Outlookalmost 25 years ago
Hydrogels for the Controlled Release of Pharmaceutical Proteinsalmost 25 years ago
Near-Infrared Inspection Complements Other QC Systemsalmost 25 years ago
Safety and Manufacturing Standardsalmost 25 years ago
Current Status of the Oral Delivery of Insulinalmost 25 years ago
Laboratory Equipment Qualificationalmost 25 years ago
Filter Integrity Testing in Liquid Applications, Revisited, Part Ialmost 25 years ago
360° Feedback - Improving the Selection Process All the Way AroundAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a holistic view of its chemical, physical, and biological properties.
Advertisement
Advertisement